Miriam Koopman
A complete genetic analysis should be part of the standard diagnostics for every patient with cancer who is eligible for treatment. WGS contributes to better, coordinated treatment advice. In this way, we reduce over- and under-treatment, while making healthcare more cost-effective and keeping it affordable.
Back to newsMore news
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
GLOW Study Ends – But WGS Remains Valuable for Glioblastoma Patients
As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …
Ten years of Hartwig Medical Foundation: a retrospect and a glimpse of the future
In its first decade, Hartwig Medical Foundation has made significant progress towards its goal of providing access to all diagnostic …
A complete genetic analysis should be part of the standard diagnostics for every patient with cancer who is eligible for treatment. WGS contributes to better, coordinated treatment advice. In this way, we reduce over- and under-treatment, while making healthcare more cost-effective and keeping it affordable.